Status:

RECRUITING

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Lead Sponsor:

Biohaven Therapeutics Ltd.

Conditions:

Parkinson Disease

Eligibility:

All Genders

40-85 years

Phase:

PHASE2

PHASE3

Brief Summary

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

Eligibility Criteria

Inclusion

  • Key
  • Male or female participants 40 to 85 years of age, inclusive, at the time of informed consent.
  • Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.
  • Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit
  • Key

Exclusion

  • Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.
  • Diagnosis of clinically significant central nervous system (CNS) disease other than PD.
  • Participants who are current smokers (defined as smoking \[in any form, e.g., tobacco smoke, electronic cigarettes, etc.\] )
  • Treatment with PD medication(s)
  • Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.

Key Trial Info

Start Date :

May 28 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

550 Patients enrolled

Trial Details

Trial ID

NCT06976268

Start Date

May 28 2025

End Date

September 1 2027

Last Update

December 12 2025

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Site-041

Los Angeles, California, United States, 90033

2

Site-031

Farmington, Connecticut, United States, 06030

3

Site-028

New Haven, Connecticut, United States, 06510

4

Site-038

Atlantis, Florida, United States, 33462